CG

Charmaine Gittleson

Percheron Therapeutics Limited | Executive Chairman, Executive Director
Ms Gittleson has international experience as a pharmaceutical physician and enterprise leader in pharmaceutical drug development, governance and risk management gained during her 15-year tenure (2005-2020) with global specialty biotechnology company. Dr Gittleson had at various times accountability for clinical research, medical safety, medical and patient related ethics for development and on market programs, providing leadership in strategic product development, planning and implementation across multiple therapeutic and rare disease areas. Gittleson held the key leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States; and Chief Medical Officer in Melbourne from 2017 until her recent retirement from corporate roles in 2020. Dr Gittleson commenced her role as Chair on 28 July, 2021.He is member of Governance Committee.

Companies and Roles

Company
Title
Tenure
Since
PER
Percheron Therapeutics Limited
  • Executive Chairman
  • Executive Director
3yrs, 2mthMar 2021
PAB
Patrys Limited
  • Non-Executive Chairman
  • Non-Executive Director
1yrs, 6mthNov 2022

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
29/11/230733,3333,006,667N/A
PER
Percheron Therapeutics Limited
29/11/230733,3333,006,667N/A
PAB
Patrys Limited
30/06/23N/AN/A8,000,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
29/11/23
Issued
3,000,000$0.060$180,000Issue of options
PER
Percheron Therapeutics Limited
29/11/23
Issued
3,000,000$0.060$180,000Issue of options
22/08/23
Issued
600,000$0.050$30,000Participation in share purchase plan
PER
Percheron Therapeutics Limited
22/08/23
Issued
600,000$0.050$30,000Participation in share purchase plan
28/04/22
Buy
6,667$0.110$733As advised by the company